drugset / Trial / NCT04493619
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer.
Timeline
- Start
- 2020-08-11
- Primary completion
- 2022-04-25
- Completion
- 2022-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PLX2853 | Unknown | 40 mg | — |
| Subject | PLX2853 | Unknown | 80 mg | — |
| Background | Carboplatin | Small molecule | — | Intravenous |